Results 21 to 30 of about 710 (119)
Aim. Carriership of CYP2C19*2 allelic variant and reduced CYP3A4 activity can affect the formation of clopidogrel’s active metabolite and, respectively, its antiplatelet effect.
K. B. Mirzaev +4 more
doaj +1 more source
Background. In our previously published studies, we demonstrated a high hemostatic activity of a low dose of exogenous fibrin monomer during its systemic administration in a model of dosed liver injury with preliminary inhibition of platelet aggregation.
V. M. Vdovin +6 more
doaj +1 more source
Spontaneous coronary artery dissection (scad) [PDF]
Spontaneous coronary artery dissection is rare disease, occurring most often in young women. Clinical manifestation is acute coronary syndrome (ACS). Patogenetic of the disease is not known.
Groch, Ladislav +2 more
core +2 more sources
Механическая поддержка кровообращения у детей: патофизиология педиатрического гемостаза и алгоритмы послеоперационного ведения [PDF]
Chronic heart failure (CHF) against the background of congenital heart disease, mostly in early childhood, or various forms of cardiomyopathies, more common in teenage age, represents an important cause of morbidity and mortality in the pediatric ...
D. V. Ryabtsev +7 more
core +2 more sources
EVALUATION OF PLATELET AGGREGATION IN CLINICAL PRACTICE
Evaluation of platelet function with subsequent modification of antiplatelet therapy regimen is one of the areas of personalized medicine. Analysis of the causes of inadequate antiplatelet action of clopidogrel, the association of residual platelet ...
K. B. Mirzaev +2 more
doaj +1 more source
О ВОЗМОЖНОСТЯХ ОСЛАБЛЕНИЯ ИНТЕНСИВНОСТИ АНТИТРОМБОЦИТАРНОЙ ТЕРАПИИ У БОЛЬНЫХ ПОСЛЕ ОСТРОГО КОРОНАРНОГО СИНДРОМА РЕЗОЛЮЦИЯ СОВЕТА ЭКСПЕРТОВ ОБЩЕСТВА СПЕЦИАЛИСТОВ ПО НЕОТЛОЖНОЙ КАРДИОЛОГИИ [PDF]
.Дата проведения: 25 октября 2017 г.
Article Editorial +1 more
core +2 more sources
Current issues of atherothrombosis prevention and treatment optimization with antiplatelet therapy in patients with cardioascular diseases are discussed.
O. V. Gaisenok
doaj +1 more source
ИЗМЕНИЛИСЬ ЛИ НАШИ ПРЕДСТАВЛЕНИЯ О НЕОБХОДИМОСТИ КЛОПИДОГРЕЛА В ЛЕЧЕНИИ КАРДИОЛОГИЧЕСКИХ БОЛЬНЫХ С ПОЯВЛЕНИЕМ БОЛЕЕ МОЩНЫХ АНТИАГРЕГАНТОВ? [PDF]
Despite the decline in cardiovascular mortality rate in recent decades due to the widespread use of antihypertensive, hypocholesterolemic and antiplatelet drugs, various manifestations of ischemic heart disease (IHD) retain one-third of the mortality ...
E. P. PANCHENKO +1 more
core +2 more sources
Aim. To study therapeutic equivalence (efficacy, safety and tolerability) of original clopidogrel (Plavix) and its generic (Egitromb) in patients of high cardiovascular risk. Material and methods.
V. V. Yakusevich +4 more
doaj +1 more source
Исследование остеопротективных эффектов тетрагидробиоптерина и клопедогрела на модели гипоэстрогенного остеопороза [PDF]
Изучение и анализ остеопротективных свойств тетрагидробиоптерина и клопидогрела при экспериментальном остеопорозе у ...
Гудырев, О. С. +4 more
core +1 more source

